

一、治療範圍

1. 食道腫瘤或腫瘤原發部位
2. 淋巴轉移病灶
3. 高風險淋巴轉移範圍

二、治療劑量 / 次數

▲輔助性放射治療 (手術後)

1. 總劑量

- (a) 殘餘腫瘤 / 腫瘤原發部位：50~50.4 GyE *
- (b) 高風險範圍：45~50.4 GyE
- (c) 照射次數：25~28 次

▲根治性放射治療 (無手術)

1. 總劑量

- (a) 腫瘤：50~50.4 GyE *
- (b) 高風險範圍：45~50.4 GyE
- (c) 照射次數：25~28 次

* 上段食道癌可考慮增加劑量至 60~66 GyE；中下段食道癌可考慮增加劑量至 60 GyE。

▲前導性放射治療 (手術前)

1. 總劑量

- (a) 腫瘤：45~50.4 GyE
- (b) 高風險範圍：45~50.4 GyE
- (c) 照射次數：25~28 次

或是

2. 總劑量

- (a) 腫瘤：41.4 GyE
- (b) 高風險範圍：41.4 GyE
- (c) 照射次數：23 次

▲根治性質子放射線治療 (無手術)

1. 總劑量

- (a) 腫瘤：60~70 GyE
照射次數：30~35 次
- (b) 高風險範圍：36~40 GyE
照射次數：20 次

▲近接放射線治療

主治醫師於遠隔放射治療後評估追加近接放射線治療
腫瘤表面處方劑量：3Gy x 4 次 或 5 Gy x 3 次

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規畫，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. International Commission on Radiation Units and Measurements. ICRU Report No 50: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: ICRU Publications 1993.
2. Cooper JS, GUO MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.

3. International Commission on Radiation Units and Measurements. ICRU Report No 62: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: ICRU Publications 1999.
4. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. *Radiation Therapy Oncology* 1999; 51: 21-26.
5. Gaspar L.E., Winter K., Kocha W., Coia L.R., Herskovic A., Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): Final report. *Cancer*. 2000;88:988-995
6. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002; 20: 1167-1174.
7. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. *J Clin Oncol* 2007; 25:4110-4117.
8. Willett CG, et al. Principles and Practice of Radiation Oncology. 5th edition: Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1131-1153.
9. Gao XS, Qiao X, Wu F, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. *Int J Radiat Oncol Biol Phys* 2007;67:389-396.
10. Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG Oncology RTOG 0436 Trial. *JAMA Oncol*. 2017 Feb 1;3(2):152-158.
11. Biere SS, van Blankenstein W, Noordman BJ, et al. Patient-reported outcomes following cetuximab addition in RTOG 0436 esophageal cancer trial: insights from long-term follow-up. *Qual Life Res*. 2024 Dec;33(12):3471-3480
12. P. van Hagen, M.C.C.M. Hulshof, J.J.B. van Lanschot, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. *N Engl J Med* 2012; 366:2074-2084.
13. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol*. 2015 Sep;16(9):1090-1098.

14. Ono T, et al. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel). 7:993, 2019
15. Lin SH, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 38: 1569-79, 2020
16. NCCN clinical practice guidelines in oncology for esophageal and esophagogastric junction cancers. Version 1, 2026.
17. QUANTEC